Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who are willing and able to sign a consent form agreeing to take part
- People whose condition is suitable for treatment using the Reduced Profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (BXB) device, as determined by the treating doctor
- People who are willing to attend follow-up appointments as required by the trial site
Who may not be able to join:
- People who have already been enrolled in this same registry before, or who would need to be enrolled in more than one treatment group at the same time
- People currently taking part in another research study or registry that could interfere with the results of this trial, unless the trial sponsor (Gore) has given approval
- People with a known severe allergy or sensitivity to heparin, including those who have previously experienced a serious reaction called Heparin-Induced Thrombocytopenia (HIT) type II, which is a condition where heparin causes a dangerous drop in platelets
- People whose life expectancy is less than 12 months due to other health conditions, or who are unlikely to be able to attend the required follow-up visits
- People who cannot tolerate blood-thinning or anti-clotting medications at the time of the procedure
- People with a known allergy to contrast dye or to materials used in the BXB device, where that allergy cannot be adequately managed
- People who are pregnant or breastfeeding at the time of signing the consent form
- People with other medical conditions that, in the investigator's judgement, could make the results difficult to interpret — for example, serious infection, blood-clotting disorders, or connective tissue conditions (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniele Branzan, Prof. Dr., TUM Klinikum
Phone: +31 627 294 665
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Freedom from device-related Serious Adverse Event (SAE) for patients treated with BXB device; Procedural Success for patients treated with BXB device
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.